Patient preferences for attributes of treatments for chronic pain associated with osteoarthritis pain and chronic low back pain that differentiate nerve-growth factor inhibitors, nonsteroidal anti-inflammatory drugs, and opioids in the United States

Abstract

Background/Purpose : Monoclonal antibodies that inhibit nerve growth factor (NGF- abs) may offer an alternative to current nonsteroidal anti- infl ammatory drug (NSAID) and opioid treatments for osteoarthritis (OA) pain and chronic low back pain (CLBP). NGF- abs differ from these treatments in several ways, including mode of administration, duration of effect, effi cacy, and safety. NGF- abs also avoid some adverse effects (AEs) associated with opioids and NSAIDs—risk of physical dependence and cardiovascular risks, respectively. However, they may be associated with the risk of rapidly progressive OA (RPOA) and other AEs not seen with opioids or NSAIDs. Our objective was to quantify patients’ preferences for attributes of treatments for chronic moderate- to- severe musculoskeletal pain associated with OA and CLBP that both differentiate NGF inhibitors, NSAIDs, and opioids and are relevant to patients.